Evidence map›Paper›PMID 22097902›Full record

ArticleBiochemistry2011

Differential roles of cysteine residues in the cellular trafficking, dimerization, and function of the high-density lipoprotein receptor, SR-BI.

Jie Hu, Zhonghua Zhang, Wen-Jun Shen, Ann Nomoto, Salman Azhar

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. HDL and Scavenger Receptor Class B Type I (SRBI).Advances in experimental medicine and biology · 2022
    Review
  4. Article
  5. Article
  6. The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. ACTH Regulation of Adrenal SR-B1.Frontiers in endocrinology · 2016
    Review
  12. Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
  13. Review
  14. New developments in selective cholesteryl ester uptake.Current opinion in lipidology · 2013
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jie HuGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, California 94304, United States.
Zhonghua Zhang
Wen-Jun Shen
Ann Nomoto
Salman Azhar
Stanford University · US

Funding

HOW DO CELLS PROCESS HIGH DENSITY LIPOPROTEINS?R01HL033881 · NHLBI · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI AZHAR, SALMAN · 1985 to 2014
$3.8M
NHLBI NIH HHS HL033881NHLBI NIH HHS R01 HL033881
6 · The paper itself

Abstract

The scavenger receptor, class B, type I (SR-BI) binds high-density lipoprotein (HDL) and mediates selective delivery of cholesteryl esters (CEs) to the liver and steroidogenic cells of the adrenal glands and gonads. Although it is clear that the large extracellular domain (ECD) of SR-BI binds HDL, the role of ECD in the selective HDL-CE transport remains poorly understood. In this study, we used a combination of mutational and chemical approaches to systematically evaluate the contribution of cysteine residues, especially six cysteine residues of ECD, in SR-BI-mediated selective HDL-CE uptake, intracellular trafficking, and SR-BI dimerization. Pretreatment of SR-BI-overexpressing COS-7 cells with a disulfide (S-S) bond reducing agent, β-mercaptoethanol (100 mM) or dithiothreitol (DTT) (10 mM), modestly but significantly impaired SR-BI-mediated selective HDL-CE uptake. Treatment of SR-BI-overexpressing COS-7 cells with the optimal doses of membrane permeant alkyl methanethiosulfonate (MTS) reagents, positively charged MTSEA or neutral MMTS, that specifically react with the free sulfhydryl group of cysteine reduced the rate of SR-BI-mediated selective HDL-CE uptake, indicating that certain intracellular free cysteine residues may also be critically involved in the selective cholesterol transport process. In contrast, use of membrane impermeant MTS reagent, positively charged MTSET and negatively charged MTSES, showed no such effect. Next, the importance of eight cysteine residues in SR-BI expression, cell surface expression, dimer formation, and selective HDL-derived CE transport was evaluated. These cysteine residues were replaced either singly or in pairs with serine, and the mutant SR-BIs were expressed in either COS-7 or CHO cells. Four mutations, C280S, C321S, C323S, and C334S, of the ECD, either singly or in various pair combinations, resulted in significant decreases in SR-BI (HDL) binding activity, selective CE uptake, and trafficking to the cell surface. Surprisingly, we found that mutation of the two remaining cysteine residues, C251 and C384 of the ECD, had no effect on either SR-BI expression or function. Other cysteine mutations and substitutions were also without effect. Western blot data indicated that single and double mutations at C280, C321, C323, and C334 residues strongly favor dimer formation. However, they are rendered nonfunctional presumably because of mutation-induced formation of aberrant disulfide linkages resulting in inhibition of optimal HDL binding and, thus, selective HDL-CE uptake. These results provide novel insights into the functional role of four cysteine residues, C280, C321, C323, and C334, of the SR-BI ECD in SR-BI expression and trafficking to the cell surface, its dimerization, and associated selective CE transport function.

Indexed as

AlkylationAmino Acid SubstitutionAnimalsChlorocebus aethiopsCHO CellsCholesterol EstersCOS CellsCricetinaeCricetulusCysteineDimerizationDown-RegulationLipoproteins, HDLMutagenesis, Site-DirectedMutant ProteinsOxidation-ReductionCholesterol EstersCysteineHDL cholesteryl esterhigh density lipoprotein receptorsLipoproteins, HDLMutant ProteinsReceptors, LipoproteinRecombinant ProteinsReducing AgentsSCARB1 protein, humanScavenger Receptors, Class B

Identifiers

PMID22097902
PMCPMC3262050
OpenAlexW273586012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.